Conclusions: After adjustment for baseline characteristics, patients with symptomatic peripheral artery disease (PAD) based on prior revascularization, rather than an abnormal ABI, had a higher rate of myocardial infarction (MI) and acute limb ischemia but with a similar composite rate of cardiovascular death, MI and stroke. No significant difference was found between ticagrelor and clopidogrel for reduction of cardiovascular or acute limb ischemic events.
Conclusions: After adjustment for baseline characteristics, patients with symptomatic peripheral artery disease (PAD) based on prior revascularization, rather than an abnormal ABI, had a higher rate of myocardial infarction (MI) and acute limb ischemia but with a similar composite rate of cardiovascular death, MI and stroke. No significant difference was found between ticagrelor and clopidogrel for reduction of cardiovascular or acute limb ischemic events.
Summary: The EUCLID trial (Examining Use of Ticagrelor vs Clopidogrel In PAD) randomized 13, 885 patients with peripheral artery disease to treatment with ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. Patients were enrolled based on an abnormal ankle-brachial index #0.80 or a previous lower extremity revascularization. This analysis focuses on the 7875 (57%) patients enrolled based on the previous lower extremity revascularization criterion. Important exclusion criteria were that patients could not be enrolled within 30 days of most recent revascularization nor if on dual antiplatelet therapy. The primary efficacy end point was a composite rate of cardiovascular death, MI, or ischemic stroke. The primary safety end point was major bleeding. Patients with a previous revascularization had a mean age of 66 years, 73% were male, and the median baseline ankle-brachial index was 0.78. When compared to those entered into the study based on ABI criteria, there was a lower % of women (27% vs 29.3%; P ¼ .004) but higher % of carotid stenosis (19% vs 15.3%; P ¼ .001), prior coronary intervention (26.3% vs 19.1%; P ¼ .001), and multilevel vascular disease (46.2% vs 40.7%; P ¼ .001). They were more commonly smokers, hyperlipidemia and more were being treated with cardioprotective medications (antiplatelets, statins) prior to enrollment. There were fewer diabetics in this group. 31.3% were asymptomatic while 4.5% were experiencing critical limb ischemia. 63.5% had endovascular revascularization while 36.3% required an open operation. The timing of most recent revascularization was nearly a third of patients in each of three time intervals: <6 months, 6-24 months, and >2 years. 7.5% of patients had prior amputation; 1.7% above knee, 1.1% below knee and the remainder less extensive. Compared with patients enrolled based on the ABI criterion, patients enrolled based previous revascularization had higher rates of the primary composite end point (11.4% vs 9.9%; P ¼ .02), myocardial infarction (5.9% vs 3.6%; P < .001), acute limb ischemia (2.5% vs 0.6%; P < .001), and major bleeding (1.8% vs 1.3%; P ¼ .01). After adjustment for baseline characteristics, patients enrolled based on previous revascularization vs those with abnormal ABI criteria had similar rates of the primary composite end point (P ¼ .12) but significantly higher rates of myocardial infarction (P ¼ .005) and acute limb ischemia (P < .001). Ticagrelor was not found to statistically improve the rates of primary or secondary efficacy or primary safety end points vs clopidogrel treatment: primary efficacy end point (11.4% vs 11.3%; P ¼ .90), all-cause mortality (9.2% vs 9.2%; P ¼ .93), acute limb ischemia (2.5% vs 2.5%; P ¼ .84), or major bleeding (1.9% vs 1.8%; P ¼ .41). The bleeding rate was no different for intracranial bleeds (both 0.6%), fatal bleeds (0.1% ticagrelor vs 0.3% clopidogrel) or minor bleeds (1.6% ticagrelor vs 1.3% clopidogrel). The median duration of follow-up was w30 months with 19 patients either lost to follow-up or of unknown status.
Comments: This subgroup analysis of the EUCLID study provides some insight into the care of patient with a prior revascularization. We must be more aware of the increased risk of myocardial infarction in these patients since it affects our attention and intensity of medical treatment. The increased incidence of acute limb ischemia is more difficult to interpret since we do not know the specific type of revascularization (angioplasty, bypass (synthetic or autogenous), location, etc.), which would affect the type of medical adjuvants we might chose to improve patency. The bottom-line for this study, however, is that either of these antiplatelets have a similar effect on cardiovascular risk reduction. It adds understanding to our use of monotherapy in these patients but much work needs to be done to determine optimal therapy.
CD98 Regulates Vascular Smooth Muscle Cell Proliferation in Atherosclerosis
Baumer Y, McCurdy S, Alcala M, Mehta N, Lee BH, Ginsberg MH, et al. Atherosclerosis 2017; 256:105-14. Conclusions: This basic science study conducted in mice demonstrates that CD98hc (a transmembrane protein involved in cell proliferation and survival and in particular the heavy chain) is required for vascular smooth muscle cell (VSMC) proliferation and that its deficiency leads to a reduced VSMC presence in the neointima. CD98hc expression in VSMC contributes to the formation of plaques that are morphologically more stable in terms of increased collagen content and reduced necrotic core area.
Summary: CD98 is a transmembrane protein made of two subunits e CD98 heavy chain (CD98hc) and one of six light chains e and is involved in cell proliferation and survival. However, its influence on atherosclerotic development is unknown. The aim of this study was to determine if CD98hc expression in VSMC plays a role in the morphologic make-up of atherosclerotic plaques by regulating VSMC function. The animal models were double knockout mice (SMC-specific deletion of CD98hc in an atherosclerotic prone mouse) compared to controls which were parent mice only prone to atherosclerosis. Aortic samples from these two groups were used to obtain VSMC for the culture experiments studying in vitro VSMC proliferation and apoptosis. Eight-to 10-week-old mice were placed on a high fat diet (HFD) for up to 16 weeks to aid in developing target atherosclerotic plaques and sacrificed at 0, 4, 8, 12, and 16 weeks after starting the HFD. The aortic sinus, root, and aorta were cut into 5 um sections for Oil Red-O staining (esterified lipids with microscopy), picrosirius red staining (collagen with polarized light microscopy) and immunohistochemistry. Immunohistochemistry of the aortic root sections were stained for SM22a (smooth muscle cells), MOMA-2 (macrophages) and CD98hc. Proper preparation and staining allowed quantification of the extent of atherosclerosis, presence of collagen, macrophages and smooth muscle cell infiltration into the plaque. Serum samples at start of HFD and at harvest were analyzed for serum cholesterol, triglyceride, and circulating leukocyte populations (T cells, B cells, monocytes, neutrophils). The in vivo knockout mouse study verses controls determined the effect of CD98hc deficiency on VSMC function on the atherosclerotic plaque. Eight-to 10-week-old mice from each group were placed on a HFD for 8 weeks and 3 days before sacrifice were injected with an agent taken up during proliferation. Upon sacrifice, the mouse aortas were collected, thinly sectioned, digested and divided into two for detect of proliferation or apoptosis. The culture results demonstrated dramatically reduced cell counts, cell proliferation and migration of the CD98 deficient samples when compared to controls. Analysis of aortic VSCM after 8 weeks of HFD showed a reduction in knockout mouse VSMC proliferation as well as increased apoptosis compared to controls. The long-term in vivo atherosclerosis study demonstrated that total plaque area was similar in both groups. However, the knockout mice showed reduced presence of VSMC within the plaque (2.1 6 0.4% vs 4.3 6 0.4% SM22a-positive area per plaque area; P < .05), decreased collagen content, as well as increased necrotic core area (25.8 6 1.9% vs 10.9 6 1.6%; P < .05) compared to controls. These results are consistent with the conclusions expressed.
Comments: Plaques stability is important for reduced acute rupture with local vascular occlusion and/or distal embolization. This basic science study adds one more element to our rather poor understanding of what it takes at the cellular level to achieve a stable atherosclerotic plaque. Summary: This is a randomized controlled trial "follow-up" of three treatments for claudication (PAT, SEP, or combination therapy). Inclusion criteria for the original study were patients with unilateral claudication due to femoropopliteal artery occlusive disease amenable to both PTA and supervised exercise. Suitable patients were treated for 3 months with best medical treatment and if their symptoms were stable were asked if they would be in the trial. After informed consent, they were randomization to PTA or SEP. The primary outcome was treadmill maximum walking distance (MWD) and Physical Function (PF) domain of the SF-36 Quality of Life questionnaire tool at 12 months. Secondary outcomes were ankle to brachial systolic blood pressure index (ABI), intermittent claudication distance (ICD), and patient-reported walking distance (PRWD), SF-36 domains except PF, King's College VascuQoL, restenosis and reintervention rates. This study was a call back to all participating patients who could be found. A detailed history cross checked by electronic and clinical records helped to ensure maximal capture of past data. A fixed load treadmill test (10 degree incline at 2.5 km/h) for a maximum of 5 minutes was conducted. All baseline variables were captured including ABI, MWD, ICD, and PRWD. The ceiling for MWD for those completing the treadmill test was 215 meters and the ceiling for PRWD was 1600 meters. The SF-36 questionnaire as well as the King's College VascuQoL for disease specific and generic evaluations were completed. All patients had an arterial duplex imaging of both legs in detail to determine any old or new lesions. The primary and secondary outcomes reflected those of the original study and by an intention to treat methodology. Of 178 patients who were initially recruited to the trial, 139 were alive at the time of follow-up (PTA, 46; SEP, 47; PTA + SEP, 46) and assessments were completed for 111 patients. Mortality before long-term evaluation was 24.4%, about 5% per year. Median time to long-term follow-up was 5.2 years. Patient demographics were similar between groups with median age 75. Sixty-nine patients (62.2%) were symptomatic and 18 (16.2%) had experienced a major cardiovascular event since their last follow-up visit. QoL outcomes demonstrated no significant difference between treatment groups. There was no significant difference observed in the primary end points of treadmill MWD or QoL outcomes, nor in the secondary end points of restenosis rates or new ipsilateral or contralateral lesions on duplex imaging. Improvement was observed in the ABI in all groups. PTA and PTA + SEP groups had a significantly higher ABI than the SEP group. Patients in all groups had subsequent interventions (PTA, 14; SEP, 10; PTA + SEP, 6). The total number of subsequent interventions was higher after PTA (n ¼ 29) compared with SEP (n ¼ 17) and PTA + SEP (n ¼ 9) but failed to reach statistical significance.
Comments: Although the title was intriguing, this study unfortunately tells us little of the natural history of the three treatment groups but does pose some interesting conclusions. Interventional therapy (PTA or open surgery) was often employed after trial completion without the reason intervention was provided. Certainly, a PTA did not protect the patient from intervention in the future and, in fact, was a more common event whether driven by patient choice, physician suggestion, or clinical need is unknown. It appears that the addition of SEP tends to decrease the perceived need for subsequent intervention. Interesting, the patients' primary end points of quality of life and treadmill MWD were not statistically improved by PTA, even with the subsequent interventions thought necessary. This does brings into question the cost effectiveness of PTA in the treatment of claudication due to femoropopliteal disease. The significant improvement in ABI following PTA, with or without SEP, did not result in improved primary outcomes that is somewhat contraintuitive but demonstrates the inconsistent of hemodynamic findings (including duplex determined stenosis) and patient perceptions.
Everolimus-Eluting Stent for Patients With Critical Limb Ischemia and Infrapopliteal Arterial Occlusive Disease
Giaquinta A, Vincenzo A, De Marco E, Veroux M, Veroux P. Vasc Endovascular Surg 2017;51:60-6.
Conclusions:
The use of an everolimus-eluting stent to provide straightline inflow to the foot in patients with rest pain or ulceration and infrapopliteal disease can provide acceptable 3-year limb salvage results.
Summary: This is a prospective, single-center registry study of patients with rest pain or minor ischemic ulceration and with distal popliteal and proximal tibial artery occlusive lesions up to 10 cm in length. The treatment was revascularization using the Xience-Prime EverolimusEluting Stent of the target greater than 70% BTK denovo lesion or restenosis consisting of 20 to 100 mm in length with a vessel diameter of 2 to 3.5 mm. Ultimately, one tibial or peroneal artery must supply in-line flow to the pedal arteries related to the ischemic area of the foot. Exclusion criteria were aneurysmal disease, prior surgery, acute thrombosis, nonatherosclerotic disease, or noncompliance with antiplatelet therapy. The primary end point was primary patency defined as freedom from restenosis of target vessel (peak systolic velocity ratio $ 2.4 on duplex imaging). Secondary end points were amputation-free survival (freedom from above ankle amputation of index limb), clinical success (Rutherford-Becker classification improvement 1 or more), wound healing (complete), immediate success, target lesion revascularization (TLR) rate due to restenosis, CLI recurrence, and the cumulative rate of freedom from death and major amputation, secondary patency, and survival rates. All end points were evaluated at 1, 2, and 3 years. Some caveats of the study: femoropopliteal disease was treated at the same time with angioplasty with provisional stenting, predilation of the target lesion with a shorter and smaller balloon was allowed, the drug-coated stent must cover the entire lesion with 5-mm overlap to normal artery above and below. Follow-up was physical examination and duplex imaging with angiography preformed for duplex demonstrated restenosis or CLI symptoms. Of 423 patients with CLI treated during the 3 year recruitment (2011) (2012) (2013) (2014) , 122 patients met study criteria. The average age was 70.9, 63.9% were male, and 60.6% had ulceration. The mean lesion length was 52.7 mm (20-100 mm) with most having extensive calcification (65.2%). The BTK was occluded in 68%. Immediate success was 100%. One and two stents were used in 60.6% and 29.5% of cases respectively. Twelve cases required three stents. Five procedural complications included four hematomas treated conservatively and one pseudoaneurysm requiring surgical repair. Patients completing follow-up were 88 at 1 year, 47 at 2 years, and 34 at 3 years. Eight patients were lost to follow-up (six at 1 year, two at 3 year). Twenty-six patients died during the 3 years due to cardiac disease (n ¼ 15) and respiratory disease (n ¼ 5), and six died from cancer. Fourteen patients required secondary angiography of the target limb: 10 required target lesion revascularization and four a new intervention. The 1-and 2/3-year primary patency rates were 88.9% and 80.1%, respectively. The survival, major amputation-free survival, and freedom from target lesion revascularization rates were: 88.1%, 93%, and 91.5% at 1-year follow-up; 75.7%, 89.3%, and 85.1% at 2-year follow-up; and 70.4%, 89.3%, and 85.1% at 3-year follow-up. The secondary patency rate was 92.2% at 1 year and 85% at 2 and 3 years. The freedom from cumulative major amputation/death rate was 82.7% at 1-year follow-up and 64.3% at 2-and 3-year follow-up, respectively. Diabetes had no significant influence on the results. Primary patency influenced major amputation rate, which was a 60% amputation rate in patients with no target artery patency vs 5.4% in patients with target patency (P ¼ .022). At 1-year follow-up, 78 (88.6%) of 88 patients improved 1 or more of their Rutherford-Becker category, and 48 (80%) of 69 patients had wound healing (maintained at 85.3% in the 34 patients at the 3-year follow-up).
Comments: This single-center study provides some data to suggest that distal popliteal/proximal tibial drug-eluting stent placement can provide acceptable midterm limb salvage without excessive reintervention rates in patients with rest pain and minor ulcerations. Those with more extensive ischemia where mild/moderate improvements in perfusion might not allow salvage are not studied. It is unfortunate that no estimation of improved distal perfusion (ABI) is provided to determine the degree of improved perfusion for comparison over time. Most investigators would have provided patient outcomes (limb salvage) as primary outcome rather than the surrogate primary patent of the target lesion restenosis.
